New York, Jan 17, 2026, 07:00 (EST) — Market closed.
- Kenvue shares closed Friday at $17.20, down 0.35%, and ticked to $17.19 in after-hours trade.
- Proxy adviser ISS recommended shareholders approve Kimberly-Clark’s planned acquisition of Kenvue.
- U.S. markets are shut on Monday for Martin Luther King Jr. Day; trading resumes Tuesday.
Kenvue Inc shares ended slightly lower on Friday after proxy adviser ISS backed Kimberly-Clark’s takeover proposal, keeping attention on a shareholder vote later this month.
The broader market went into the long weekend on a quiet note, with the S&P 500 down 0.06% on Friday. U.S. stock markets are closed on Monday for the Martin Luther King Jr. holiday.
ISS said “support for the transaction is warranted,” while flagging what it called a “sustained negative market reaction” and uncertainty tied to litigation around Kenvue products. Kimberly-Clark proposed buying Tylenol-maker Kenvue for more than $40 billion, a deal that would bring together brands including Band-Aids and Huggies, Reuters reported. Reuters
Kenvue closed at $17.20, after trading between $17.06 and $17.29, with about 57.4 million shares changing hands.
A filing showed Kenvue on Friday moved to supplement its merger disclosures after shareholder litigation and demand letters pressed for more detail ahead of the vote. The company said it was acting to avoid the risk of delaying the deal and said its board still unanimously recommends Kenvue shareholders vote “FOR” the merger and related proposals; the filing also reiterated that Kenvue holders are slated to receive $3.50 in cash plus an exchange ratio of 0.14625 of a Kimberly-Clark share, while laying out banker analyses and fee disclosures.
Some of those banker ranges sit well above where Kenvue trades now, but they are part of fairness work and lean heavily on projections, discount rates and assumptions that can swing the output.
The structure matters for the tape. With stock in the mix, the implied value of the offer shifts with Kimberly-Clark’s share price, not just Kenvue’s.
But the path is still messy. Court fights over disclosures can complicate the calendar, and product-liability headlines can flare without warning. If the deal breaks or drags, Kenvue stock could reprice back toward a pure standalone view.
With markets reopening Tuesday, investors will watch for fresh proxy-adviser calls, any new court filings in the stockholder suits, and further SEC updates tied to the merger materials.
